Merck & Co. Inc. (NYSE: MRK) on Wednesday shared topline results from the Phase 3 trial of an investigational, once-daily, oral, two-drug, single-tablet regimen of doravirine/islatravir (DOR/ISL) in ...
The US government late Wednesday took the rare step of suing Gilead for infringing on four government-owned patents related to the HIV drug Truvada (emtricitabine/tenofovir disoproxil fumarate) for ...
U.S. FDA Grants Priority Review of New Drug Application for Gilead’s Once-Daily HIV Treatment of Bictegravir Plus Lenacapavir – Novel Investigational Combination Pairs Bictegravir, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results